Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Assets (2016 - 2020)

China Pharma Holdings filings provide 8 years of Other Non-Current Assets readings, the most recent being $222996.0 for Q2 2020.

  • On a quarterly basis, Other Non-Current Assets fell 55.69% to $222996.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $222996.0, a 55.69% decrease, with the full-year FY2019 number at $109908.0, down 91.37% from a year prior.
  • Other Non-Current Assets hit $222996.0 in Q2 2020 for China Pharma Holdings, down from $331038.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.6 million in Q2 2017 to a low of $109908.0 in Q4 2019.
  • Median Other Non-Current Assets over the past 5 years was $1.2 million (2018), compared with a mean of $1.1 million.
  • Biggest five-year swings in Other Non-Current Assets: soared 104.92% in 2017 and later tumbled 91.37% in 2019.
  • China Pharma Holdings' Other Non-Current Assets stood at $1.1 million in 2016, then plummeted by 34.81% to $709796.0 in 2017, then soared by 79.48% to $1.3 million in 2018, then tumbled by 91.37% to $109908.0 in 2019, then surged by 102.89% to $222996.0 in 2020.
  • The last three reported values for Other Non-Current Assets were $222996.0 (Q2 2020), $331038.0 (Q1 2020), and $109908.0 (Q4 2019) per Business Quant data.